Monoclonal Antibody Treatment
September 3, 2021
Monoclonal Antibody Treatment
What is it used for?
The monoclonal antibody infusion emergency use authorization (EUA) for COVID-19 that we currently offer is REGEN-COV. REGEN-COV is authorized for the treatment of mild to moderate confirmed COVID-19 in outpatients 12 years and older whose symptoms onset occurred within the past 10 days and are at high risk of progression to severe COVID-19 and/or hospitalization.
What is it and what does it do?
REGEN-COV consists of the monoclonal antibodies casirivimab and imdevimab, administered together. Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful viruses. This therapy is designed to help block the COVID-19 virus and prevent the virus from further infecting healthy cells.
Do I qualify?
Trousdale Medical Center is able to provide monoclonal antibody infusion therapy if you meet the following criteria:
- Tested positive for COVID-19 and
- Symptom onset occurred within the past 10 days and
- Have one of the following high-risk conditions:
- Obesity or being overweight
- Pregnancy
- Chronic Kidney Disease
- Diabetes
- 65 years of age or older
- Immunosuppressive disease or receiving immunosuppressive treatment
- Heart or Lung Disease
- Sickle Cell Disease
- Neurodevelopmental Disease
- Medical related technological dependence
Patients that qualify may present to our Emergency Department to be evaluated for treatment with a Monoclonal Antibody Infusion.
What are some reasons I may not qualify?
- Hospitalized due to COVID-19
- Require oxygen therapy due to COVID-19 or increase in baseline oxygen flow rate due to COVID-19
- It has been greater than 10 days since COVID-19 symptoms started
- Weight less than 88 pounds
Additional locations
Click on the following link to find other locations providing Monoclonal Antibody therapy to high-risk patients for post exposure prophylaxis (prevention) of COVID-19.